Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon

NCT01280266 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Raynaud Phenomenon

Interventions

DRUG: Udenafil or Amlodipine

Sponsor

Seoul National University Hospital

Collaborators

[object Object]